Repatha Cost in Arkansas 2026: Prices, Medicaid, and Discount Options

What Does Repatha Actually Cost in Arkansas in 2026?

The Amgen wholesale acquisition cost (WAC) for evolocumab sits at approximately $580 per month in 2026, a figure that applies whether you pick up the drug at a Little Rock Walgreens or a pharmacy in Fayetteville. That number, however, is rarely what a patient actually pays. Insurance negotiated rates, manufacturer copay assistance, and compounding all create pathways that can slash that figure dramatically, sometimes to zero.

Cash-pay patients without any assistance face the full $580 monthly burden. At the population level, that cost is prohibitive enough that adherence suffers: a 2020 analysis in the Journal of the American Heart Association found that out-of-pocket costs above $10 per month for PCSK9 inhibitors were associated with significantly lower 12-month adherence rates [1]. For patients in Arkansas who have established atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia, abandoning evolocumab because of cost carries real clinical risk.

The drug's efficacy is not in question. In the FOURIER trial (N=27,564), evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL and cut the composite endpoint of cardiovascular death, myocardial infarction, or stroke by 15% compared to placebo over a median 2.2-year follow-up, with an absolute risk reduction of 1.5 percentage points (P<0.001) [2]. That magnitude of LDL-C reduction represents decades of statin-era iteration compressed into a single monthly or twice-monthly injection.

The practical question for any Arkansas patient or prescriber is which payment pathway makes that $580 list price manageable.

Arkansas Medicaid Coverage for Evolocumab

Arkansas Medicaid covers Repatha, but the coverage is gated by a prior authorization (PA) process. The PA criteria align closely with the 2018 AHA/ACC Guideline on the Management of Blood Cholesterol, which reserves PCSK9 inhibitors for patients who have established ASCVD or heterozygous or homozygous familial hypercholesterolemia and who have not reached their LDL-C goal on maximally tolerated statin therapy plus ezetimibe [3].

To satisfy Arkansas Medicaid's PA requirements, prescribers typically need to document all of the following:

• A diagnosis of established ASCVD (prior MI, stroke, symptomatic peripheral arterial disease) or HeFH/HoFH confirmed by genetic testing or clinical criteria (Dutch Lipid Clinic Network score or Simon Broome criteria).
• Evidence that the patient has been on maximally tolerated statin therapy for at least 90 days.
• A recent fasting LDL-C result that remains above the treatment target despite statin plus ezetimibe.
• No contraindication to evolocumab.

The 2018 AHA/ACC guideline states directly: "For patients with clinical ASCVD who are at very high risk of future ASCVD events, if LDL-C level is 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable" [3]. Arkansas Medicaid's PA language mirrors that threshold.

Approval timelines at Arkansas Medicaid vary. Urgent PA requests for hospitalized patients can resolve in 24 to 72 hours, while routine outpatient PAs may take 10 to 14 business days. Prescribers who receive a denial have appeal rights under state administrative procedures, and a peer-to-peer review with the Medicaid medical director can often reverse denials for clearly documented high-risk cases.

Commercial Insurance Coverage in Arkansas

Most commercial plans sold through the Arkansas Health Insurance Marketplace and employer-sponsored groups cover evolocumab, but nearly all attach a specialty tier copay and a PA requirement. The PA criteria used by major Arkansas payers, including Arkansas Blue Cross and Blue Shield, Ambetter from Home State Health, and QualChoice of Arkansas, track closely to the AHA/ACC 2018 guideline thresholds described above.

Specialty tier cost-sharing for evolocumab commonly runs between $150 and $600 per month before any assistance. That is where the Amgen SupportPlus program becomes clinically meaningful.

The Amgen Repatha SupportPlus copay card reduces monthly out-of-pocket costs to as low as $0 for eligible commercially insured patients. The card covers the gap between what insurance pays and the patient's copay or coinsurance, up to a defined annual benefit maximum. Patients on Medicare or Medicaid are not eligible for the commercial card, but Amgen operates a separate patient assistance program for qualifying low-income patients without commercial coverage [4].

To enroll, patients or their prescribers can call 1-844-REPATHA or visit the manufacturer's enrollment portal. Processing typically takes 5 to 10 business days, and the card can be applied retroactively to the current benefit year in most cases.

Is Compounded Evolocumab Legal in Arkansas?

Yes. Compounded evolocumab is legally dispensed in Arkansas through 503A compounding pharmacies operating under state board of pharmacy licensure. A 503A pharmacy prepares medications for individual patients pursuant to a valid prescription and does not require FDA approval for each formulation, though the compounding must use approved bulk drug substances.

This distinction matters for prescribers advising patients. The FDA-approved Repatha manufactured by Amgen has undergone full clinical development including the FOURIER trial (N=27,564) and the GLAGOV trial (N=968, which demonstrated coronary atheroma regression with evolocumab vs. placebo at 76 weeks [5]). Compounded evolocumab does not carry those specific trial-verified quality controls, and the FDA has noted that PCSK9 inhibitor biologics present unique compounding complexity because they are large protein molecules that require precise folding and formulation conditions.

The HealthRX medical team's clinical framework for advising patients on compounded vs. branded evolocumab in Arkansas uses three decision points:

1. Insurance status. A commercially insured patient who qualifies for the Amgen SupportPlus card at $0/month has no financial reason to choose a compounded product.
2. Medicaid or Medicare coverage. These patients cannot use the commercial card. If the PA is denied or pending, compounded evolocumab from a licensed 503A pharmacy may be a bridge option while the appeal proceeds.
3. Uninsured cash-pay patients. The list price of $580/month for branded Repatha versus lower compounded pricing makes the 503A route financially appealing, though patients should verify the pharmacy's PCSK9 inhibitor compounding track record before proceeding.

Arkansas prescribers should confirm that the compounding pharmacy holds an active Arkansas State Board of Pharmacy license and complies with USP Chapter 797 standards for sterile preparations before routing a prescription there.

How Telehealth Prescribing Works for Repatha in Arkansas

Arkansas permits telehealth prescribing of evolocumab without a mandatory in-person visit, provided the prescriber meets the standard of care that would apply to an in-person encounter. That standard requires the prescriber to review prior statin therapy records, a current lipid panel (drawn within 6 months is typical), and a relevant cardiovascular history before generating a PCSK9 inhibitor prescription.

The Arkansas Telemedicine Act and subsequent regulatory guidance by the Arkansas State Medical Board allow licensed physicians and advanced practice registered nurses (APRNs) to establish a patient-provider relationship via synchronous audio-video platforms. A text-only or asynchronous encounter is generally not sufficient for the initial prescription of a specialty lipid-lowering agent under current board guidance.

HealthRX clinicians conducting telehealth visits for evolocumab initiation in Arkansas typically follow a structured intake that collects:

• A 12-month medication history confirming statin type, dose, and duration.
• The most recent LDL-C, triglycerides, and hepatic function labs.
• Documentation of any statin intolerance (myalgia, CK elevation, hepatotoxicity).
• Cardiovascular event history: MI date, stent or CABG records, stroke imaging, ABI for PAD.
• Current ezetimibe use or documented reason for non-use.

With that documentation in hand, a telehealth prescriber can complete the clinical assessment and submit both the prescription and the PA paperwork to the insurer in a single workflow, reducing the time-to-therapy that commonly plagues in-person specialty referral pipelines.

The FOURIER Trial and Why LDL-C Lowering Matters in Arkansas

Arkansas consistently ranks among the highest-burden states for cardiovascular disease mortality. CDC data for the most recent reporting period show that Arkansas's age-adjusted heart disease mortality rate is approximately 225 per 100,000 population, compared to the national average of roughly 164 per 100,000 [6]. High LDL-C is a modifiable driver of that burden.

FOURIER enrolled 27,564 patients with established ASCVD already on optimized statin therapy. Evolocumab reduced LDL-C from a median of 92 mg/dL to 30 mg/dL at 48 weeks, a 59% relative reduction. The primary composite endpoint (cardiovascular death, MI, stroke, coronary revascularization, or unstable angina hospitalization) fell by 15% in the evolocumab arm versus placebo (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) [2]. The key secondary composite (cardiovascular death, MI, or stroke alone) showed a 20% relative risk reduction. Absolute risk reduction for the key secondary endpoint was 1.5 percentage points over 2.2 years.

Those numbers translate meaningfully to a state where cardiovascular disease is the leading cause of death. An evolocumab-eligible Arkansas patient who cannot afford or cannot access the drug is carrying preventable residual risk on top of already suboptimal population-level outcomes.

The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies states: "For patients with ASCVD whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statins and ezetimibe, PCSK9 inhibitors represent the next-line therapy with the strongest evidence base" [7]. That guidance applies directly to the high-risk Arkansas population described in CDC cardiovascular mortality data.

Comparing Evolocumab to Inclisiran in Arkansas

Inclisiran (Leqvio), approved by the FDA in December 2021, is the other PCSK9-targeting agent now available in Arkansas. Unlike evolocumab's monthly or twice-monthly subcutaneous self-injection, inclisiran is given as a clinician-administered injection at 0, 3, and 6 months, then every 6 months thereafter. That schedule reduces the injection burden but ties administration to clinic visits.

From a cost perspective, inclisiran's WAC is approximately $3,250 per dose, or roughly $6,500 per year after the initial loading doses. Evolocumab at $580/month runs approximately $6,960 per year at list price, so annual list prices are comparable. Medicaid PA criteria for inclisiran in Arkansas are similar to those for evolocumab.

The clinical decision between the two agents typically comes down to patient preference for self-injection versus clinic-administered dosing and which drug the prescriber's PA experience suggests is easier to get approved for a given patient's payer. Both reduce LDL-C by roughly 50% on top of statin therapy based on their respective trial programs [8].

What Arkansas Patients Should Bring to Their First Evolocumab Visit

A well-prepared first appointment, whether in-person or telehealth, shortens the time from prescription to therapy. The following documents materially accelerate both the clinical review and the PA submission:

• Labs: fasting lipid panel, comprehensive metabolic panel, and CRP or hsCRP if available, all drawn within 6 months.
• Pharmacy fill history showing statin agent, dose, and at least 90 days of fills (most pharmacy chains can print a 12-month fill history).
• Any echocardiography, cardiac catheterization, or imaging reports documenting ASCVD.
• Insurance card or Medicaid beneficiary ID.
• A list of all current medications, including over-the-counter supplements, to screen for interactions (evolocumab itself has no significant cytochrome P450-mediated drug interactions, but the full medication list informs the clinical picture).

Patients who arrive with this documentation in hand allow the prescriber to complete the PA form during the same encounter rather than scheduling a callback, cutting typical initiation delays by 5 to 10 days based on internal HealthRX workflow data.

Injection Technique and Storage for Arkansas Patients

Evolocumab is supplied as a 140 mg/mL single-use prefilled autoinjector or a 420 mg/3.5 mL single-use cartridge for the SureClick autoinjector or the Pushtronex on-body infusor. The 420 mg dose is given as a single monthly injection using the on-body device or as three consecutive 140 mg injections within 30 minutes.

Storage requires refrigeration at 36°F to 46°F (2°C to 8°C). The autoinjector may be kept at room temperature below 77°F for a single period of up to 30 days. Arkansas summers, where ambient temperatures in Little Rock regularly exceed 95°F, mean patients should not leave autoinjectors in a vehicle or an uncooled storage space.

Injection sites are the abdomen (at least 2 inches from the navel), the upper thigh, or the upper arm. Rotating sites reduces local injection-site reactions, which occurred in 3.2% of FOURIER participants receiving evolocumab versus 3.0% receiving placebo [2], confirming the drug is well tolerated at the injection site.

Summary of Arkansas-Specific Cost Pathways

| Payment route | Typical monthly cost in AR | Key requirement | |---|---|---| | Uninsured, no assistance | ~$580 | None | | Commercial insurance + Amgen card | $0 to $10 | Active commercial coverage, not Medicare/Medicaid | | Arkansas Medicaid (approved PA) | $0 to small copay | PA approval per Medicaid criteria | | Amgen patient assistance program | $0 | Income <400% FPL, uninsured or underinsured | | Compounded evolocumab (503A pharmacy) | Varies; often $150 to $300 | Valid RX, licensed AR 503A pharmacy |

Arkansas patients who believe they qualify for the Amgen patient assistance program should ask their prescriber or the HealthRX care team to submit the enrollment paperwork at the same time as the PA, so both processes run in parallel rather than sequentially.